Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2016, Article ID 6162182, 7 pages
http://dx.doi.org/10.1155/2016/6162182
Review Article

The Role of [18F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1

1Westmead Hospital, Cnr Hawkesbury and Darcy Rd, Westmead, NSW 2145, Australia
2University of Sydney, Camperdown, NSW, Australia
3Nuclear Medicine, Westmead Children’s Hospital, Westmead, NSW, Australia

Received 15 August 2016; Revised 15 November 2016; Accepted 21 November 2016

Academic Editor: Vahit Ozmen

Copyright © 2016 David Tovmassian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C.-C. H. Stucky, K. N. Johnson, R. J. Gray et al., “Malignant Peripheral Nerve Sheath Tumors (MPNST): the mayo clinic experience,” Annals of Surgical Oncology, vol. 19, no. 3, pp. 878–885, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Rasmussen and J. M. Friedman, “NF1 gene and neurofibromatosis 1,” American Journal of Epidemiology, vol. 151, no. 1, pp. 33–40, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Kamran, A. Shinagare, S. Howard, J. Hornick, and N. Ramaiya, “A-Z of malignant peripheral nerve sheath tumors,” Cancer Imaging, vol. 12, no. 3, pp. 475–483, 2012. View at Publisher · View at Google Scholar
  4. J. Wasa, Y. Nishida, S. Tsukushi et al., “MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas,” American Journal of Roentgenology, vol. 194, no. 6, pp. 1568–1574, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Matsumine, K. Kusuzaki, T. Nakamura et al., “Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 7, pp. 891–900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Tonsgard, “Clinical manifestations and management of neurofibromatosis type 1,” Seminars in Pediatric Neurology, vol. 13, no. 1, pp. 2–7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. E. Ferner, J. D. Lucas, M. J. O'Doherty et al., “Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 68, no. 3, pp. 353–357, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Cardona, M. Schwarzbach, U. Hinz et al., “Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours,” European Journal of Surgical Oncology, vol. 29, no. 6, pp. 536–541, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Bredella, M. Torriani, F. Hornicek et al., “Value of PET in the assessment of patients with neurofibromatosis type I,” American Journal of Roentgenology, vol. 189, no. 4, pp. 928–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. E. Ferner, J. F. Golding, M. Smith et al., “[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study,” Annals of Oncology, vol. 19, no. 2, pp. 390–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Karabatsou, T.-R. Kiehl, D. M. Wilson, A. Hendler, and A. Guha, “Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1,” Neurosurgery, vol. 65, no. 4, pp. A160–A170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. V. S. Warbey, R. E. Ferner, J. T. Dunn, E. Calonje, and M. J. O'Doherty, “FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 5, pp. 754–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. R. Benz, J. Czernin, S. M. Dry et al., “Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign,” Cancer, vol. 116, no. 2, pp. 451–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Moharir, K. London, R. Howman-Giles, and K. North, “Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 7, pp. 1309–1317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. L. Tsai, L. Drubach, F. Fahey, M. Irons, S. Voss, and N. J. Ullrich, “[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation,” Journal of Neuro-Oncology, vol. 108, no. 3, pp. 469–475, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Derlin, K. Tornquist, S. Münster et al., “Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1,” Clinical Nuclear Medicine, vol. 38, no. 1, pp. e19–e25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Meany, E. Dombi, J. Reynolds et al., “18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST),” Pediatric Blood and Cancer, vol. 60, no. 1, pp. 59–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Salamon, S. Veldhoen, I. Apostolova et al., “18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off,” European Radiology, vol. 24, no. 2, pp. 405–412, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Chirindel, M. Chaudhry, J. O. Blakeley, and R. Wahl, “18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization,” Journal of Nuclear Medicine, vol. 56, no. 3, pp. 379–385, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. F. J. Rodriguez, A. L. Folpe, C. Giannini et al., “Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems,” Acta Neuropathologica, vol. 123, no. 3, pp. 295–319, 2012. View at Publisher · View at Google Scholar
  21. M. C. Adams, T. G. Turkington, J. M. Wilson, and T. Z. Wong, “A systematic review of the factors affecting accuracy of SUV measurements,” American Journal of Roentgenology, vol. 195, no. 2, pp. 310–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. L. M. Velasquez, R. Boellaard, G. Kollia et al., “Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies,” Journal of Nuclear Medicine, vol. 50, no. 10, pp. 1646–1654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Salamon, L. Papp, Z. Tóth et al., “Nerve sheath tumors in neurofibromatosis type 1: assessment of whole-body metabolic tumor burden using F-18-FDG PET/CT,” PLoS ONE, vol. 10, no. 12, Article ID e0143305, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Broski, G. B. Johnson, B. M. Howe et al., “Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors,” Skeletal Radiology, vol. 45, no. 8, pp. 1097–1105, 2016. View at Publisher · View at Google Scholar
  25. A. Van Der Gucht, O. Zehou, S. Djelbani-Ahmed et al., “Metabolic tumour burden measured by 18F-FDG PET/CT predicts malignant transformation in patients with neurofibromatosis type-1,” PLoS ONE, vol. 11, no. 3, Article ID e0151809, 2016. View at Publisher · View at Google Scholar